AstraZeneca's big CKD promises come to fruition as Farxiga wins approval in patients regardless of diabetes status

Almost a year after nabbing a groundbreaking approval for heart failure patients with or without type 2 diabetes, AstraZeneca’s Farxiga claimed another notable OK on Friday.

The SGLT2 inhibitor got the FDA green light for chronic kidney disease in adults at risk of progression, the British pharma said late Friday afternoon. Much like the heart failure approval, Friday’s win is also indicated for patients regardless of if they have type 2 diabetes. Farxiga was originally approved to treat type 2 diabetes back in 2014.